HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, Y. Articles by Qiao, L. Search for Related Content PubMed PubMed Citation Articles by Huang, Y. Articles by Qiao, L. Pubmed/NCBI databases Substance via MeSH

Turning On/Off Tumor-Specific CTL Response during Progressive Tumor Growth¹

Department of Microbiology & Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153

Therapeutic vaccinations used to induce CTLs and treat firmly established tumors are generally ineffective. To understand the mechanisms underlying the failure of therapeutic vaccinations, we investigated the fate of tumor-specific CD8⁺ T cells in tumor-bearing mice with or without vaccinations. Our data demonstrate that tumor-specific CD8⁺ T cells are activated at the early stage of tumor growth, tumor-specific CTL response reaches a maximal level during progressive tumor growth, and tumor-specific CD8⁺ T cells lose cytolytic function at the late stage of tumor growth. The early stage therapeutic vaccination induces efficient antitumor activity by amplifying the CTL response, whereas the late-stage therapeutic vaccination is invalid due to tumor-induced dysfunction of CD8⁺ T cells. However, at the late stage, tumor-specific CD8⁺ T cells are still present in the periphery. These tumor-specific CD8⁺ T cells lose cytolytic activity, but retain IFN- secretion function. In contrast to in vitro cultured tumor cells, in vivo growing tumor cells are more resistant to tumor-specific CTL killing, despite an increase of tumor Ag gene expression. Both tumor-induced CD8⁺ T cell dysfunction at the late stage and immune evasion developed by in vivo growing tumor cells contribute to an eventual inefficacy of therapeutic vaccinations. Our study suggests that it is important to design a vaccination regimen according to the stages of tumor growth and the functional states of tumor-specific CD8⁺ T cells.

This article has been cited by other articles:

				M. O. Kilinc, K. S. Aulakh, R. E. Nair, S. A. Jones, P. Alard, M. M. Kosiewicz, and N. K. Egilmez Reversing Tumor Immune Suppression with Intratumoral IL-12: Activation of Tumor-Associated T Effector/Memory Cells, Induction of T Suppressor Apoptosis, and Infiltration of CD8+ T Effectors J. Immunol., November 15, 2006; 177(10): 6962 - 6973. [Abstract] [Full Text] [PDF]

				H. A. Doyle, J. Zhou, M. J. Wolff, B. P. Harvey, R. M. Roman, R. J. Gee, R. A. Koski, and M. J. Mamula Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity J. Biol. Chem., October 27, 2006; 281(43): 32676 - 32683. [Abstract] [Full Text] [PDF]